Implantable Loop Recorders in Patients with Brugada Syndrome: the BruLoop Study

Background And Aims: Available data on continuous rhythm monitoring by implantable loop recorders (ILRs) in patients with Brugada syndrome (BrS) are scarce. The aim of this multi-centre study was to evaluate the diagnostic yield and clinical implication of a continuous rhythm monitoring strategy by ILRs in a large cohort of BrS patients and to assess the precise arrhythmic cause of syncopal episodes.

Methods: A total of 370 patients with BrS and ILRs (mean age 43.5 ± 15.9, 33.8% female, 74.1% symptomatic) from 18 international centers were included. Patients were followed with continuous rhythm monitoring for a median follow-up of 3 years.

Results: During follow-up, an arrhythmic event was recorded in 30.7% of symptomatic patients [18.6% atrial arrhythmias (AAs), 10.2% bradyarrhythmias (BAs), and 7.3% ventricular arrhythmias (VAs)]. In patients with recurrent syncope, the aetiology was arrhythmic in 22.4% (59.3% BAs, 25.0% VAs, and 15.6% AAs). The ILR led to drug therapy initiation in 11.4%, ablation procedure in 10.9%, implantation of a pacemaker in 2.5%, and a cardioverter-defibrillator in 8%. At multivariate analysis, the presence of symptoms [hazard ratio (HR) 2.5, P = .001] and age >50 years (HR 1.7, P = .016) were independent predictors of arrhythmic events, while inducibility of ventricular fibrillation at the electrophysiological study (HR 9.0, P < .001) was a predictor of VAs.

Conclusions: ILR detects arrhythmic events in nearly 30% of symptomatic BrS patients, leading to appropriate therapy in 70% of them. The most commonly detected arrhythmias are AAs and BAs, while VAs are detected only in 7% of cases. Symptom status can be used to guide ILR implantation.

Citing Articles

Asymptomatic Brugada syndrome: Navigating implantable cardioverter-defibrillator implantation dilemma.

Lima M, Almeida A, Matos D, Cavaco D, Adragao P HeartRhythm Case Rep. 2025; 10(12):941-945.

PMID: 39897681 PMC: 11781890. DOI: 10.1016/j.hrcr.2024.09.008.

Increased pacemaker implantation and mortality rates in relatives of patients with early-onset sinus node dysfunction: can genetics explain all?.

Conte G Europace. 2024; 26(12).

PMID: 39533833 PMC: 11630514. DOI: 10.1093/europace/euae289.

aTrial arrhythmias in inhEriTed aRrhythmIa Syndromes: results from the TETRIS study.

Conte G, Bergonti M, Probst V, Morita H, Tfelt-Hansen J, Behr E Europace. 2024; 26(12).

PMID: 39527076 PMC: 11630530. DOI: 10.1093/europace/euae288.

References

Mascia G, Della Bona R, Ameri P, Canepa M, Porto I, Parati G . Brugada syndrome and syncope: a practical approach for diagnosis and treatment. Europace. 2020; 23(7):996-1002. DOI: 10.1093/europace/euaa370. View

Scrocco C, Ben-Haim Y, Devine B, Tome-Esteban M, Papadakis M, Sharma S . Role of subcutaneous implantable loop recorder for the diagnosis of arrhythmias in Brugada syndrome: A United Kingdom single-center experience. Heart Rhythm. 2021; 19(1):70-78. DOI: 10.1016/j.hrthm.2021.08.034. View

Sacher F, Arsac F, Wilton S, Derval N, Denis A, de Guillebon M . Syncope in Brugada syndrome patients: prevalence, characteristics, and outcome. Heart Rhythm. 2012; 9(8):1272-9. DOI: 10.1016/j.hrthm.2012.04.013. View

Probst V, Veltmann C, Eckardt L, Meregalli P, Gaita F, Tan H . Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. Circulation. 2010; 121(5):635-43. DOI: 10.1161/CIRCULATIONAHA.109.887026. View

Hamilton G, ODonnell D, Han H . Brugada syndrome and undifferentiated syncope: use of an implantable loop recorder to document causation. Med J Aust. 2018; 209(3):113-114. DOI: 10.5694/mja17.01117. View

Hernandez-Ojeda J, Arbelo E, Jorda P, Borras R, Campuzano O, Sarquella-Brugada G . The role of clinical assessment and electrophysiology study in Brugada syndrome patients with syncope. Am Heart J. 2019; 220:213-223. DOI: 10.1016/j.ahj.2019.10.016. View

Mascia G, Crotti L, Groppelli A, Canepa M, Merlo A, Benenati S . Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis. Int J Cardiol. 2022; 357:88-94. DOI: 10.1016/j.ijcard.2022.03.028. View

Sacher F, Probst V, Iesaka Y, Jacon P, Laborderie J, Mizon-Gerard F . Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation. 2006; 114(22):2317-24. DOI: 10.1161/CIRCULATIONAHA.106.628537. View

Brugada J, Katritsis D, Arbelo E, Arribas F, Bax J, Blomstrom-Lundqvist C . 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2019; 41(5):655-720. DOI: 10.1093/eurheartj/ehz467. View

10.

Michowitz Y, Kronborg M, Glikson M, Nielsen J . The '10 commandments' for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021; 42(42):4295. DOI: 10.1093/eurheartj/ehab699. View

11.

Champagne J, Philippon F, Gilbert M, Molin F, Blier L, Nault I . The Brugada syndrome in Canada: a unique French-Canadian experience. Can J Cardiol. 2007; 23 Suppl B:71B-75B. PMC: 2794469. DOI: 10.1016/s0828-282x(07)71014-0. View

12.

Antzelevitch C, Yan G, Ackerman M, Borggrefe M, Corrado D, Guo J . J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Heart Rhythm. 2016; 13(10):e295-324. PMC: 5035208. DOI: 10.1016/j.hrthm.2016.05.024. View

13.

Conte G, Chierchia G, Wauters K, de Asmundis C, Sarkozy A, Levinstein M . Pulmonary vein isolation in patients with Brugada syndrome and atrial fibrillation: a 2-year follow-up. Europace. 2013; 16(4):528-32. DOI: 10.1093/europace/eut309. View

14.

Mascia G, Della Bona R, Ameri P, Canepa M, Porto I, Brignole M . Brugada syndrome and syncope: A systematic review. J Cardiovasc Electrophysiol. 2020; 31(12):3334-3338. DOI: 10.1111/jce.14787. View

15.

Sakhi R, Assaf A, Theuns D, Verhagen J, Szili-Torok T, Roos-Hesselink J . Outcome of Insertable Cardiac Monitors in Symptomatic Patients with Brugada Syndrome at Low Risk of Sudden Cardiac Death. Cardiology. 2020; 145(7):413-420. PMC: 7592947. DOI: 10.1159/000507075. View

16.

Sieira J, Conte G, Ciconte G, Chierchia G, Casado-Arroyo R, Baltogiannis G . A score model to predict risk of events in patients with Brugada Syndrome. Eur Heart J. 2017; 38(22):1756-1763. DOI: 10.1093/eurheartj/ehx119. View

17.

Cronin E, Bogun F, Maury P, Peichl P, Chen M, Namboodiri N . 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. J Arrhythm. 2019; 35(3):323-484. PMC: 6595359. DOI: 10.1002/joa3.12185. View

18.

Perez M, Mahaffey K, Hedlin H, Rumsfeld J, Garcia A, Ferris T . Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019; 381(20):1909-1917. PMC: 8112605. DOI: 10.1056/NEJMoa1901183. View

19.

Brignole M, Cecchi F, Anastasakis A, Crotti L, Deharo J, Elliott P . Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management. Int J Cardiol. 2022; 370:330-337. DOI: 10.1016/j.ijcard.2022.10.153. View

20.

Priori S, Wilde A, Horie M, Cho Y, Behr E, Berul C . HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013; 10(12):1932-63. DOI: 10.1016/j.hrthm.2013.05.014. View